Ongoing tracking is meant to spot very rare risks – like the connection between the Johnson & Johnson shot and Guillain-Barré syndrome. And it relies on public reporting.
Articles on Guillain-Barré Syndrome
Displaying all articles
Non-specific illnesses, such as headache and fatigue, are common, as are mental illnesses such as depression and anxiety.
The TGA has reported a handful of cases of the autoimmune disorder Guillain-Barré syndrome following the AstraZeneca vaccine.
As if the symptoms of COVID-19 were not disturbing enough, physicians have noted a rare neurological condition that emerges during some severe cases of this viral infection.
One way the novel coronavirus might enter the brain is through the olfactory nerves in the nose.
The 2015 Zika outbreak in South America brought the virus to global attention. But tracing the history of the virus in West Africa can give clues to tackling future outbreaks.
Top contributors
-
Professor of Immunology and Infectious Diseases, Harvard University
-
Junior Doctor and Dementia Researcher, Wolfson Institute of Preventive Medicine, Queen Mary University of London
-
Manager of Ambulatory Pharmacy Services, University of Virginia
-
Clinical Lecturer in Psychiatry, UCL
-
Assistant Professor of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai
-
Honorary Senior Lecturer in Virology and President of Research-Aid Networks, University of Kent
-
Associate Professor, Neurology, Wake Forest University
-
Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Associate Professor of Critical Care Medicine, Neurology, and Neurosurgery, University of Pittsburgh